MediciNova Company Insiders
| MNOV Stock | USD 2.00 0.05 2.56% |
MediciNova's insiders are aggressively selling. The analysis of the overall insider sentiment regarding MediciNova suggests that vertually all insiders are panicking. MediciNova employs about 13 people. The company is managed by 5 executives with a total tenure of roughly 31 years, averaging almost 6.0 years of service per executive, having 2.6 employees per reported executive.
MediciNova's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2022-11-28 | Hideki Nagao | Disposed 6754 @ 2.25 | View | ||
| 2022-11-17 | Hideki Nagao | Disposed 309 @ 2.18 | View |
Monitoring MediciNova's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
MediciNova |
MediciNova Management Team Effectiveness
The company has return on total asset (ROA) of (0.0951) % which means that it has lost $0.0951 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1332) %, meaning that it created substantial loss on money invested by shareholders. MediciNova's management efficiency ratios could be used to measure how well MediciNova manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.17 in 2024. At this time, MediciNova's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 4.8 M in 2024, whereas Other Assets are likely to drop slightly above 101.4 K in 2024.Common Stock Shares Outstanding is likely to drop to about 24.6 M in 2024. Net Loss is likely to drop to about (13.3 M) in 2024
MediciNova Workforce Comparison
MediciNova is regarded second in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 68.0. MediciNova retains roughly 13.0 in number of employees claiming about 19% of equities under Health Care industry.
MediciNova Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MediciNova insiders, such as employees or executives, is commonly permitted as long as it does not rely on MediciNova's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MediciNova insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Beaver Carolyn a day ago Acquisition by Beaver Carolyn of 15000 shares of MediciNova at 5.4 subject to Rule 16b-3 | ||
Nagao Hideki over a month ago Acquisition by Nagao Hideki of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3 | ||
Obrien Geoffrey over three months ago Disposition of 11318 shares by Obrien Geoffrey of MediciNova at 2.46 subject to Rule 16b-3 | ||
Beaver Carolyn over three months ago Acquisition by Beaver Carolyn of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3 | ||
Beaver Carolyn over three months ago Acquisition by Beaver Carolyn of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3 | ||
Nagao Hideki over six months ago Acquisition by Nagao Hideki of 20000 shares of MediciNova subject to Rule 16b-3 | ||
Masatsune Okajima over six months ago Exercise of in-the-money or at-the-money derivative position by Masatsune Okajima of 8400 shares of MediciNova | ||
Geoffrey OBrien over six months ago Acquisition by Geoffrey OBrien of 84000 shares of MediciNova subject to Rule 16b-3 |
MediciNova Notable Stakeholders
A MediciNova stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MediciNova often face trade-offs trying to please all of them. MediciNova's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MediciNova's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jason CPA | CFO Officer | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Yuichi MD | President, CoFounder | Profile | |
| MD MPH | Chief Director | Profile | |
| John CPA | Controller | Profile |
About MediciNova Management Performance
The success or failure of an entity such as MediciNova often depends on how effective the management is. MediciNova management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MediciNova management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MediciNova management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.14) | (0.14) |
Please note, the imprecision that can be found in MediciNova's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MediciNova. Check MediciNova's Beneish M Score to see the likelihood of MediciNova's management manipulating its earnings.
MediciNova Workforce Analysis
Traditionally, organizations such as MediciNova use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MediciNova within its industry.MediciNova Manpower Efficiency
Return on MediciNova Manpower
| Revenue Per Employee | 76.9K | |
| Revenue Per Executive | 200K | |
| Net Loss Per Employee | 659.3K | |
| Net Loss Per Executive | 1.7M | |
| Working Capital Per Employee | 3.7M | |
| Working Capital Per Executive | 9.6M |
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.